Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman FLX device was superior to oral anti-coagulant medication in reducing bleeding risks following cardiac ablation.

The study also showed the Watchman FLX Left Atrial Appendage Closure, or LAAC, Device was as effective as oral anticoagulants in patients with atrial fibrillation following cardiac ablation, according to a statement released over the weekend.

The clinical study, called OPTION, compared the Watchman FLX to direct oral anticoagulants and warfarin for the reduction of stroke risk in patients with non-valvular atrial fibrillation following cardiac ablation.

The trial met the primary safety endpoint of non-procedural major bleeding or clinically relevant non-major bleeding at 36 months and the primary efficacy endpoint of all-cause death, stroke or systemic embolism at 36 months, the company said.

Boston Sci (BSX) presented the data at the American Heart Association’s Scientific Sessions 2024 meeting. The data was also published in The New England Journal of Medicine.

The company’s latest-generation Watchman FLAX Pro LAAC Device was approved in 2023.